Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.23, demonstrating a +2.22% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Google DeepMind's new report maps four pathways from AGI to artificial superintelligence. Here's how scaling, paradigm shifts ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he insists it will actually ship products.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

These properties make PIRTM suitable as the safety-critical inner loop for AI inference engines, certified control systems, and any computation that must be auditable after the fact. Classical ...

This repository contains the complete mathematical, philosophical, and practical framework for the Sophia Axiom—a synthesis of ancient Gnostic cosmology, modern theoretical physics, and information ...

Ask the publishers to restore access to 500,000+ books. An icon used to represent a menu that can be toggled by interacting with this icon. A line drawing of the Internet Archive headquarters building ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...